Literature DB >> 29299667

Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration.

Mathilde Small1,2,3, Isabelle Treilleux4, Coline Couillault3,5, Daniel Pissaloux4,6, Géraldine Picard2, Sandrine Paindavoine4,6, Valery Attignon6, Qing Wang6, Véronique Rogemond1,2, Stéphanie Lay2, Isabelle Ray-Coquard7, Jacobus Pfisterer8, Florence Joly9, Andreas Du Bois10, Dimitri Psimaras2, Nathalie Bendriss-Vermare3,5, Christophe Caux3,5, Bertrand Dubois3,5, Jérôme Honnorat11,12,13, Virginie Desestret1,2,3.   

Abstract

Paraneoplastic cerebellar degenerations with anti-Yo antibodies (Yo-PCD) are rare syndromes caused by an auto-immune response against neuronal antigens (Ags) expressed by tumor cells. However, the mechanisms responsible for such immune tolerance breakdown are unknown. We characterized 26 ovarian carcinomas associated with Yo-PCD for their tumor immune contexture and genetic status of the 2 onconeural Yo-Ags, CDR2 and CDR2L. Yo-PCD tumors differed from the 116 control tumors by more abundant T and B cells infiltration occasionally organized in tertiary lymphoid structures harboring CDR2L protein deposits. Immune cells are mainly in the vicinity of apoptotic tumor cells, revealing tumor immune attack. Moreover, contrary to un-selected ovarian carcinomas, 65% of our Yo-PCD tumors presented at least one somatic mutation in Yo-Ags, with a predominance of missense mutations. Recurrent gains of the CDR2L gene with tumor protein overexpression were also present in 59% of Yo-PCD patients. Overall, each Yo-PCD ovarian carcinomas carried at least one genetic alteration of Yo-Ags. These data demonstrate an association between massive infiltration of Yo-PCD tumors by activated immune effector cells and recurrent gains and/or mutations in autoantigen-encoding genes, suggesting that genetic alterations in tumor cells trigger immune tolerance breakdown and initiation of the auto-immune disease.

Entities:  

Keywords:  Anti-tumor immunity; Autoantigen-encoding gene mutations; Ovarian cancer; Paraneoplastic cerebellar degeneration

Mesh:

Substances:

Year:  2018        PMID: 29299667     DOI: 10.1007/s00401-017-1802-y

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  27 in total

1.  IFN-γ is a therapeutic target in paraneoplastic cerebellar degeneration.

Authors:  Lidia Yshii; Béatrice Pignolet; Emilie Mauré; Mandy Pierau; Monika Brunner-Weinzierl; Oliver Hartley; Jan Bauer; Roland Liblau
Journal:  JCI Insight       Date:  2019-04-04

2.  The Discovery of Anti-Yo (Anti-PCA1) Antibody in Patients with Paraneoplastic Cerebellar Degeneration: Opening a Window into Autoimmune Neurological Disease.

Authors:  John E Greenlee; H Robert Brashear
Journal:  Cerebellum       Date:  2022-07-26       Impact factor: 3.648

3.  Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration.

Authors:  Elise Peter; Isabelle Treilleux; Valentin Wucher; Emma Jougla; Alberto Vogrig; Daniel Pissaloux; Sandrine Paindavoine; Justine Berthet; Géraldine Picard; Véronique Rogemond; Marine Villard; Clémentine Vincent; Laurie Tonon; Alain Viari; Jérôme Honnorat; Bertrand Dubois; Virginie Desestret
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-07-12

Review 4.  Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities.

Authors:  Céline M Laumont; Allyson C Banville; Mara Gilardi; Daniel P Hollern; Brad H Nelson
Journal:  Nat Rev Cancer       Date:  2022-04-07       Impact factor: 69.800

5.  Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes.

Authors:  Francesc Graus; Alberto Vogrig; Sergio Muñiz-Castrillo; Jean-Christophe G Antoine; Virginie Desestret; Divyanshu Dubey; Bruno Giometto; Sarosh R Irani; Bastien Joubert; Frank Leypoldt; Andrew McKeon; Harald Prüss; Dimitri Psimaras; Laure Thomas; Maarten J Titulaer; Christian A Vedeler; Jan J Verschuuren; Josep Dalmau; Jerome Honnorat
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-05-18

6.  Anti-Yo antibody-positive paraneoplastic cerebellar degeneration in a patient with possible cholangiocarcinoma: A case report and review of the literature.

Authors:  Yue Lou; Shan-Hu Xu; Si-Ran Zhang; Qin-Fen Shu; Xiao-Li Liu
Journal:  World J Clin Cases       Date:  2021-06-16       Impact factor: 1.337

7.  Identification of an Metabolic Related Risk Signature Predicts Prognosis in Cervical Cancer and Correlates With Immune Infiltration.

Authors:  Chunliang Shang; Jiaming Huang; Hongyan Guo
Journal:  Front Cell Dev Biol       Date:  2021-06-24

Review 8.  Paraneoplastic cerebellar degeneration in platinum-responsive endometrial cancer: A case report and review of literature.

Authors:  Michalis Liontos; Oraianthi Fiste; Danai Drakopoulou; Nikolaos Thomakos; Kalliroi Goula; Flora Zagouri; Maria Anagnostouli; Meletios-Athanasios Dimopoulos
Journal:  Gynecol Oncol Rep       Date:  2021-06-29

9.  Intensive Combination Immunotherapy and Neuroinflammation Resolution in a Child With Anti-PCA-1 (Yo) Paraneoplastic Syndrome and 2 Malignancies.

Authors:  Guillermo Philipps; Elizabeth D Tate; Michael R Pranzatelli
Journal:  Child Neurol Open       Date:  2018-10-01

10.  Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies.

Authors:  Clément Vialatte de Pémille; Giulia Berzero; Mathilde Small; Dimitri Psimaras; Marine Giry; Maïlys Daniau; Marc Sanson; Jean-Yves Delattre; Jérôme Honnorat; Virginie Desestret; Agusti Alentorn
Journal:  Br J Cancer       Date:  2018-06-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.